index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

94

 

NOTICES

156

 

 

MOTS CLES

Anxiété Anti-Bacterial Agents Treatment Ethics Pharmaco-Épidémiologie Adalimumab Bacterial Burden Abus d'antibiotiques Drug reaction Placebo Management Spondyloarthritis Network meta-analysis Immune-related adverse events Antibiotics Angiotensin-converting enzyme inhibitors Apremilast Adverse side effects Vigibase® Spondylitis Atopic dermatitis Etanercept Autoimmunity Adolescent Antimicrobial Stewardship Antimicrobiens Infliximab Stability BTK protein Aging Biological Therapy Biomarkers Drug survival Psoriatic arthritis Biological therapy Biologic drug Immunotherapy Prostate cancer Biologics Auto-immune hepatitis Atrial fibrillation Auto-Diagnostic Endocrine toxicity Access to care Axial spondyloarthritis Sacroiliitis Biologic Addiction Antibiotic misuse Albinism Arrhythmia Beta-lactam antibiotics Glucocorticoids Angiotensin receptor blockers Accelerometer Psoriasis ArtThese Bacterial rhinosinusitis Antimicrobials Sipuleucel-T Ankylosing spondylitis Biomédicaments Intensive care Amyloidosis Biologic therapy Méta-Analyse Cancer Cardiomyopathy Anti-HCV Direct Acting Antivirals DAA Primary adrenal insufficiency Pharmacovigilance Pregnancy ASDAS Immune checkpoint inhibitors Anticancer drugs Pharmacoepidemiology Autoimmune diseases Ustekinumab Dermatology Biosimilar Pharmaceuticals Systematic review Graft-versus-host disease Meta-Analysis Alcohol Epidemiology Alitretinoin Azathioprine Cardio-oncology Antimicrobial resistance Ankylosing COVID-19 Cardiotoxicity Antibiotic resistance Quality of life Apre-milast Arthritis Anxiety Anti-TNF Acute Myeloid Leukaemia AML

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS